Holen Sie sich die Stockscreener-App
2.02
0.49%
-0.010
Handel nachbörslich:
1.98
-0.04
-1.98%
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Update - MarketBeat
Lucid Capital Markets initiates coverage on Adagene stock with Buy rating - Investing.com India
Adagene Inc. Amends Collaboration Agreement with Exelixis to Advance SAFEbody Technology for Cancer Therapy - Quiver Quantitative
Adagene Expands SAFEbody® Collaboration and License - GlobeNewswire
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - MarketScreener
Breakthrough Cancer Drug Technology: Adagene's 'Invisible' ADC Platform Expands to Third Program - Stock Titan
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 38.1% in August - Defense World
Using economic indicators to assess Adagene Inc. Depositary Receipt potential2025 Historical Comparison & Verified Short-Term Plans - newser.com
Quantitative breakdown of Adagene Inc. Depositary Receipt recent moveProduct Launch & High Return Trade Opportunity Guides - Newser
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Using data tools to time your Adagene Inc. Depositary Receipt exit2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 70.6% - MarketBeat
Adagene’s ADG126 to be Highlighted in Two Presentations at - GlobeNewswire
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - The Manila Times
Adagene Inc. Showcases ADG126 at CSCO Meeting with Promising Results in Advanced MSS Colorectal Cancer - Quiver Quantitative
30% Response Rate: Adagene's Novel Cancer Drug Shows Promise in Hard-to-Treat Colorectal Cancer Trial - Stock Titan
Former YERVOY developer Axel Hoos joins Adagene as advisor - Investing.com
Adagene Inc. Appoints Dr. Axel Hoos as Executive Advisor to Enhance Immuno-Oncology Initiatives - Quiver Quantitative
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - The Manila Times
Former $2.5B Scorpion CEO & YERVOY Developer: Adagene's CTLA-4 Platform Could Transform Cancer Care - Stock Titan
Is Adagene Inc. Depositary Receipt’s growth already priced inJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک
Can Adagene Inc. Depositary Receipt maintain sales growthJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - خودرو بانک
What data driven models say about Adagene Inc. Depositary Receipt’s futureWeekly Stock Recap & Weekly High Momentum Picks - Newser
Adagene to Participate in Two Investor Conferences in September - The Manila Times
Biotech Innovator Adagene Scheduled for Major Wall Street Healthcare Conferences in September 2025 - Stock Titan
Will Adagene Inc. Depositary Receipt see short term momentumTrade Performance Summary & Smart Swing Trading Techniques - Newser
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
HC Wainwright Issues Pessimistic Forecast for Adagene (NASDAQ:ADAG) Stock Price - Defense World
How to read the order book for Adagene Inc. Depositary Receipt2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Q3 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
H.C. Wainwright lowers Adagene stock price target to $7 on development path clarity - Investing.com
Adagene's 22.4% Surge: Clinical Breakthroughs and Strategic Alliances Ignite Biotech Volatility - AInvest
How institutional ownership impacts Adagene Inc. Depositary Receipt stockPortfolio Gains Report & Risk Controlled Daily Plans - Newser
What indicators show strength in Adagene Inc. Depositary ReceiptJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser
Published on: 2025-08-12 20:31:18 - Newser
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Cancer Drug Breakthrough: Adagene's ADG126 Doubles Standard Survival Rate as Sanofi Backs Development - Stock Titan
Is Adagene Inc. Depositary Receipt still worth holding after the dipFree Low Risk Picks for Daily Trading - Newser
Why Adagene Inc. Depositary Receipt is moving todayStock Price Prediction Using AI Tools - Newser
Q2 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
Using R and stats models for Adagene Inc. Depositary Receipt forecastingFree AI Forecast for Trending Stocks - Newser
Adagene (NASDAQ:ADAG) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Leerink Partners Begins Coverage on Adagene (NASDAQ:ADAG) - Defense World
Leerink Partners initiates Adagene stock with Outperform rating on cancer drug potential - Investing.com India
What are analysts’ price targets for Adagene Inc. Depositary Receipt in the next 12 monthsAccelerated investment success - Jammu Links News
Why did ADAG's Q4 2020 EPS miss forecasts drastically? - AInvest
Published on: 2025-07-28 00:29:47 - jammulinksnews.com
Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest
Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire
Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):